Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pediatric Alopecia Areata: Diagnosis and Treatment Options
Description
Pediatric alopecia areata differs from adult disease because there are no FDA-approved treatments under age 12, the psychological burden can be greater than the visible severity, and children may tolerate therapies differently. Treatment choice depends on age, extent of hair loss, rapid progression, atopy, and emotional impact. For patchy disease, first-line therapy remains topical corticosteroids such as clobetasol or mometasone, often used in cycles to reduce side effects, and may be combined with topical minoxidil. Topical JAK inhibitors are promising but evidence is limited, though some are available for children as young as 2 years. Intralesional steroids can work for limited disease, but injections are difficult in children, so comfort measures like cooling sprays can help. For rapidly progressive or more severe cases, systemic corticosteroids can be used as a bridge, especially with low-dose minoxidil, but growth, bone density, and glucose must be monitored. Low-dose oral minoxidil can be used with weight-based dosing when needed. Contact immunotherapy is another option, especially when other treatments are limited; DPCP and squaric acid appear similarly effective, though DPCP has more data and modified home-based protocols may improve adherence, despite cost and access barriers. Atopic dermatitis can complicate contact immunotherapy, and dupilumab may improve tolerance in patients with atopy. For JAK inhibitors under age 12, off-label tofacitinib is often favored because of oral solution availability, pediatric dosing experience, and potentially stronger efficacy than baricitinib; live vaccines require temporary holding of JAK therapy. Cranial prostheses and nonprofit resources can also be important supportive measures for affected families.
View moreConclusions
- For limited pediatric alopecia areata, high-potency topical corticosteroids remain the first-line treatment, with reasonable efficacy and manageable side effects when used in cycles.
- Topical JAK inhibitors may be useful in children, but the evidence is still limited and largely extrapolated from adult data.
- Intralesional corticosteroid injections can be effective for localized disease, but in children the experience is often difficult, so comfort measures and practical techniques matter.
- Rapidly progressive or new-onset disease may justify short-course systemic corticosteroids, especially as a bridge to longer-term therapy, though relapse and monitoring concerns are important.
- In severe pediatric alopecia areata under age 12, low-dose oral minoxidil is a practical off-label option with weight-based dosing used in the absence of approved therapies.
- Contact immunotherapy remains a useful option when other treatments are limited, with DPCP and SADBE appearing similarly effective, though access, cost, and side effects are barriers.
- A modified DPCP protocol may improve tolerability, reduce adverse events, and maintain efficacy by allowing subclinical sensitization and home-based treatment.
- Children with atopic dermatitis may respond better when contact immunotherapy is paired with dupilumab, which can also reduce eczema flares and improve treatment tolerance.
- Among JAK inhibitors, ritlecitinib is the only FDA-approved pediatric option, but tofacitinib may offer higher response rates in younger children and baricitinib has supportive real-world evidence despite being off-label.
- For children needing live vaccines, JAK inhibitors require temporary interruption around vaccination, and supportive resources such as cranial prostheses and nonprofit wig programs are important parts of care.
- The International Delphi Consensus (2025)
- Randomized controlled trial on low-dose dexamethasone oral mini-pulse
- Connecting Families to Care: Nonprofit Wig Resources for Children#10.1111/pde.70075